Published in Vaccine on April 01, 1994
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun (1996) 2.14
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun (1996) 1.71
Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun (1998) 1.42
Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun (1998) 1.40
Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun (2000) 1.35
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine (2007) 1.28
Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun (2006) 1.27
Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect Immun (1995) 1.24
In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release (2011) 1.20
Construction of yeast strains with high cell surface lipase activity by using novel display systems based on the Flo1p flocculation functional domain. Appl Environ Microbiol (2002) 1.17
Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol (1995) 1.17
Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol (2009) 1.12
Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun (1998) 1.12
Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun (1996) 1.08
Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol (2009) 1.06
Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology (2002) 1.04
Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine (2010) 1.02
Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology (2010) 1.02
Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect Immun (1997) 1.01
Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev (1999) 1.00
Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc Natl Acad Sci U S A (1996) 0.99
Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun (1999) 0.99
Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect Immun (1998) 0.99
The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infect Immun (1999) 0.95
Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun (1996) 0.95
Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol (2004) 0.94
Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res (2012) 0.92
The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. J Virol (1995) 0.91
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun (1996) 0.88
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharm J (2011) 0.88
Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun (2001) 0.87
Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect Immun (2000) 0.87
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Nasal immunization with homogenate and peptide antigens induces protective immunity against Trichinella spiralis. Infect Immun (2002) 0.84
In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin A. BMC Microbiol (2012) 0.84
Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun (2007) 0.84
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun (2001) 0.83
Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity. Mol Pharm (2010) 0.83
Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid. Iran J Pharm Res (2012) 0.81
Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One (2013) 0.81
Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone. Clin Diagn Lab Immunol (1998) 0.80
Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei. BMC Immunol (2011) 0.79
A field trial of autogenous Moraxella bovis bacterin administered through either subcutaneous or subconjunctival injection on the development of keratoconjunctivitis in a beef herd. Can Vet J (2003) 0.79
The development of an AIDS mucosal vaccine. Viruses (2010) 0.79
Protective role of purified cysteine proteinases against Fasciola gigantica infection in experimental animals. Korean J Parasitol (2012) 0.78
Display of the Viral Epitopes on Lactococcus lactis: A Model for Food Grade Vaccine against EV71. Biotechnol Res Int (2013) 0.78
Establishment and Evaluation of an in vitro M Cell Model using C2BBe1 Cells and Raji Cells. Biosci Microflora (2011) 0.77
The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol (1998) 0.77